


Monoclonal Antibodies

- **BLAZE Trial**
- 1°-↓VL
- 2° – hosp, T to sxs improve
- High Risk pts
- Outpt
- ↓ hosp
- EUA

Bamlanivimab



- Regeneron
- Combo, infusion x1
- Mild to severe COVID
- Prelim similar to Bam
- Data not published
- EUA

Casirivimab

Idevimab

